NYSE$KVUE
Kenvue Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Kenvue reported Q2 2025 net sales of $3.84B with net income of $420M and diluted EPS of $0.22.
Net sales declined 4% to $3.84 billion as organic growth was offset by portfolio and currency effects. Net income was $420 million with diluted EPS of $0.22; Self Care, Skin Health & Beauty, and Essential Health segments drove the quarter amid ongoing separation-related costs.
- Q2 net sales $3.84B (-4% YoY).
- Net income $420M; diluted EPS $0.22.
- Brand portfolio spans consumer health categories post-J&J spin.
- Self Care and Skin Health remain core growth engines.
- Competition from private label and promotional intensity persist.
Headline financials
Revenue & EPS history
Kenvue · Revenue · Quarterly
$3.84B
Revenue by segment
Kenvue · $3.92B total across 3 segments · Q3 2023
- Self Care$1.61B+6.4%41.2%
- Essential Health$1.18B+3.0%30.2%
- Skin Health & Beauty$1.12B-0.4%28.6%
Forward guidance
Kenvue discusses outlook, capital allocation, and key risks for upcoming periods in the filing.
Tailwinds
- Kenvue cites execution on strategic and operating priorities.
- Liquidity supports ongoing operations and investment.
- Management monitors demand and cost trends.
Headwinds
- Macro uncertainty may pressure volumes or margins.
- Competitive dynamics in core markets.
- One-time items can affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q2 2025
+2.0%
Avg return
Earnings day
+3.1%
Avg return
5 days after
+2.8%
Avg return
30 days after
57%
8 / 14 earnings
Positive
+15.7%
Q3 2025
Best reaction
-7.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | -1.2% | +0.2% | |
| Q4 2025 | +0.9% | +2.9% | -5.5% | |
| Q3 2025 | +15.7% | +17.5% | +18.1% | |
| Q2 2025 | +1.5% | +2.1% | -13.2% | |
| Q1 2025 | +4.3% | +2.4% | -6.0% | |
| Q4 2024 | -4.5% | +0.8% | +12.9% | |
| Q3 2024 | +5.2% | +5.1% | +1.5% | |
| Q2 2024 | +13.4% | +15.6% | +23.7% | |
| Q1 2024 | +7.2% | +7.7% | -2.4% | |
| Q4 2022 | -0.2% | +3.1% | +12.9% | |
| Q4 2023 | -5.8% | -6.2% | -2.4% | |
| Q3 2023 | -7.7% | -5.7% | +2.6% | |
| Q2 2023 | -4.0% | +0.5% | -8.5% | |
| Q1 2023 | -0.5% | -0.8% | +4.5% | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro